钟志远
时间:2019-12-26

钟志远 19742月生,江西赣州人。苏州大学特聘教授,国家杰出青年基金获得者,国家“万人计划”创新领军人才,苏州大学生物医用高分子材料重点实验室主任,放射医学与辐射防护国家重点实验室靶向放射性药物创新与转化中心主任,药剂学国际顶级期刊J. Controlled ReleaseIF 9.776)副主编。1995年吉林工业大学(现吉林大学)获学士学位,1998年中国科学院长春应用化学研究所获硕士学位,2002年荷兰屯特大学获博士学位。2002-2007年荷兰屯特大学任助理教授。20074月起受聘为苏州大学特聘教授。2011-2012年担任苏州工业园区生物产业发展有限公司(苏州生物纳米园)副总裁。研究领域涉及生物医用高分子材料、纳米药物及肿瘤靶向治疗。在国际主流期刊发表论文280篇,论文共被引用21000多次,H-因子74。自2014年起连续7年入选中国高被引学者榜单,2018年起连续3年入选全球高被引科学家。申请了50多项国家和国际发明专利(其中授权20多项),11项专利技术已转让。应邀在重要国际学术会议上做邀请报告50多次。

2015-2019年担任美国化学会期刊Biomacromolecules副主编。担任Mater. Today, Biomacromolecules, Nanotechnology, Mater. Today Chem., PLoS One, J. Gene Med., J. Biomater. Sci. Polym. Ed.等国际期刊编委,《药学学报》及英文刊Acta Pharmaceutica Sinica B编委,新型高分子材料与控制释放系列高水平国际学术会议主席,中国材料研究学会高分子材料与工程分会常务理事等。获得了美国化学会的“生物大分子/大分子青年研究者奖”、德国洪堡基金会“贝塞尔研究奖”、日本控制释放学会颁发的“亚洲药物释放系统突破技术奖”等国际奖励。入选国家“万人计划”创新领军人才、国家杰出青年科学基金获得者(杰青结题特优)、国家百千万人才工程并授予“有突出贡献中青年专家”荣誉称号、科技部中青年科技创新领军人、江苏特聘教授、苏州市十佳魅力科技人物等。享受国务院政府特殊津贴。2018年当选美国医学与生物工程院会士(AIMBE Fellow)


代表性论文

1.    N. Yu, Y.F. Zhang, J.Y. Li, W.X. Gu, S.J. Yue, B. Li, F.H. Meng, H.L. Sun*, R. Haag, J.D. Yuan, andZ.Y. Zhong*, Daratumumab Immunopolymersome-Enabled Safe and CD38-Targeted Chemotherapy and Depletion of Multiple Myeloma, Adv. Mater.2021, 2007787

2.    Y.H. Wei, Y.P. Sun, J.J. Wei, X.Y. Qiu, F.H. Meng*, G. Storm*, J.D. Yuan, Z.Y. Zhong*, Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo, J. Control. Release2021, 337,  521-529.

3.    W.X. Gu, R.B. Qu, F.H. Meng*,J.L.M. Cornelissen*, andZ.Y. Zhong*,Polymeric Nanomedicines Targeting Hematological Malignancies, J. Control. Release 2021, 337, 571-588.

4.    Q.Y. Fan, Y.Y. Liu, G.H. Cui, Z.Y. Zhong*,andC. Deng*, Brain delivery of Plk1 inhibitor via chimaeric polypeptide polymersomes for safe and superb treatment of orthotopic glioblastoma, J. Control. Release 2021, 329, 1139-1149.

5.    W.X. Gu, F.H. Meng*, R. Haag, andZ.Y. Zhong*, Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation, J. Control. Release 2021, 329, 676-695.

6.    C. Gao, Q. Cheng, J.W. Wei, C. Sun, S.Y. Lu, C.H.T. Kwong, S.M.Y. Lee, Z.Y. Zhong*, and R.B. Wang*, Bioorthogonal supramolecular cell-conjugation for targeted hitchhiking drug delivery, Mater. Today2020, 40, 9-17.

7.    C. Deng*, Q. Zhang, J.Q. Guo, X.F. Zhao, and Z.Y. Zhong*, Robust and **art polypeptide-based nanomedicines for targeted tumor therapy, Adv. Drug Deliv. Rev. 2020, 160, 199-211.

8.    H.L. Sun, and Z.Y. Zhong*, 100th Anniversary of Macromolecular Science Viewpoint: Biological Stimuli-Sensitive Polymer Prodrugs and Nanoparticles for Tumor-Specific Drug Delivery, ACS Macro Lett. 2020, 9, 1292-1302.

9.    Y.H. Wei, F.H. Meng*, G. Storm, and Z.Y. Zhong*, Transferrin-Binding Peptide Functionalized Polymersomes Mediate Targeted Doxorubicin Delivery to Colorectal Cancer In Vivo, J. Control. Release 2020, 319, 407-415.

10.  Y.N. Zhong, F.H. Meng*, W. Zhang, B. Li, J. van Hest, andZ.Y. Zhong*, CD44-Targeted Vesicles Encapsulating Granzyme B as Artificial Killer Cells for Potent Inhibition of Human Multiple Myeloma in Mice, J. Control. Release2020, 320, 421-430.

11.  Y. Yan, Y.Y. Dong, S.J. Yue, X.Y. Qiu, H.L. Sun*, andZ.Y. Zhong*, Dually Active Targeting Nanomedicines Based on a Direct Conjugate of Two Purely Natural Ligands for Potent Chemotherapy of Ovarian Tumor, ACS Appl. Mater. Interfaces2019, 11, 46548-46557.

12.  H.L. Sun, X.L. Gu, Q. Zhang, H. Xu, Z.Y. Zhong*, and C. Deng*, Cancer Nanomedicines Based on Synthetic Polypeptides, Biomacromolecules 2019, 20, 4299-4311.

13.  X.L. Gu, Z.H. Zhu, Y.H. Wei, G.L. Wang, F.H. Meng, Z.Y. Zhong*, and C. Deng*, Nano-Agents Based on Poly(ethylene glycol)-b-Poly(L-thyroxine) Block Copolypeptide for Enhanced Dual-Modality Imaging and Targeted Tumor Radiotherapy, Small 2019, 15, 1902577.

14.  Y. Zou, Y.H. Wei, J. Bao, F.R. Yao, Z.K. Li, Y.P. Sun, F.H. Meng*, C.H. Hu, G. Storm, andZ.Y. Zhong*, Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Melanoma, Theranostics2019, 9, 8061-8072.

15.  H.L. Sun, Z.Y. Zhong*, and J. Feijen, The Fifth Symposium on Innovative Polymers for Controlled Delivery, September 14-17, 2018, Suzhou, China, J. Control. Release2019, 307, 410-412.

16.  W.X. Gu, J.N. An, H. Meng, N. Yu, Y.N. Zhong, F.H. Meng*, Y. Xu*, J.L.M. Cornelissen, andZ.Y. Zhong*, CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma, Adv. Mater.2019, 1904742.

17.  H.Z. Qin, Y. Jiang, J. Zhang, C. Deng*, and Z.Y. Zhong*, Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals a High Safety and Potency against Human Glioblastoma in Mice, Mol. Pharmaceutics 2019, 16, 3711-3719.

18.  M. Qiu, J. Ouyang, Y.H. Wei, J. Zhang, Q. Lan, C. Deng*, and Z.Y. Zhong*, Selective cell penetrating peptide-functionalized envelope-type chimaeric lipopepsomes boost systemic RNAi therapy for lung tumor, Adv. Healthcare Mater. 2019, 1900500.

19.  K. Huang, Y.H. He, Z.H. Zhu, J.K. Guo, G.L. Wang, C. Deng*, and Z.Y. Zhong*, Small, Traceable, Endosome-Disrupting and Bioresponsive Click Nanogels Fabricated via Microfluidics for CD44-Targeted Cytopla**ic Delivery of Therapeutic Proteins, ACS Appl. Mater. Interfaces 2019, 11, 22171-22180.

20.  X.L. Gu, Y.H. Wei, Q.Y. Fan, H.L. Sun, R. Cheng, Z.Y. Zhong*, and C. Deng*, cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo, J. Control. Release 2019, 301, 110-118.

21.  Y. Zou, J.J. Wei, Y.F. Xia, F.H. Meng*, J.D. Yuan, andZ.Y. Zhong*,Targeted chemotherapy for subcutaneous and orthotopic non-**all cell lung tumors with cyclic RGD-functionalized and disulfide-crosslinked polymersomal doxorubicin, Signal Transduction and Targeted Therapy2018, 3, 32.

22.  Y. Jiang, J. Zhang*, F.H. Meng, and Z.Y. Zhong*,Apolipoprotein E Peptide-Directed Chimeric Polymersomes Mediate an Ultrahigh-Efficiency Targeted Protein Therapy for Glioblastoma,ACS Nano2018, 12, 11070-11079.

23.  L. Cheng, Y. Yang, F.H. Meng*, Z.Y. Zhong*, Protein Nanotherapeutics as an Emerging Modality for Cancer Therapy, Adv. Healthcare Mater.2018, 7, 1800685.

24.  Y.N. Shi, Y. Jiang, J.S. Cao, W.J. Yang, J. Zhang*, F.H. Meng, and Z.Y. Zhong*,Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes,J. Control. Release2018, 292, 163-171.

25.  H.L. Sun, Y.F. Zhang, and Z.Y. Zhong*, Reduction-Sensitive Polymeric Nanomedicines: An Emerging Multifunctional Platform for Targeted Cancer Therapy, Adv. Drug Deliv. Rev.2018, 132, 16-32.

26.  M. Qiu, Z.Q. Zhang, Y.H. Wei, H.L. Sun, F.H. Meng, C. Deng*, and Z.Y. Zhong*, Small-Sized and Robust Chimaeric Lipopepsomes: A Simple and Functional Platform with High Protein Loading for Targeted Intracellular Delivery of Protein Toxin In Vivo, Chem. Mater. 2018, 30, 6831-6838.

27.  W.J. Yang, Y.H. Wei, J. Zhang, Z.Y. Zhong*, F.H. Meng*,Granzyme B-loaded, cell-selective penetrating and reduction-responsive polymersomes effectively inhibit progression of orthotopic human lung tumor in vivo, J. Control. Release2018, 290, 141-149.

28.  H.L. Sun, Y.Y. Dong, J. Feijen*, and Z.Y. Zhong*, Peptide-Directed Polymeric Nanomedicines for Precision Cancer Therapy, J. Control. Release2018, 290, 11-27.

29.  Y. Jiang, W.J. Yang, J. Zhang*, F.H. Meng, and Z.Y. Zhong*,Protein Toxin Chaperoned by LRP-1 Targeted Virus-Mimicking Vesicles Induces High-Efficiency Glioblastoma Therapy In Vivo,Adv. Mater.2018, 30, 1800316.

30.  W.J. Yang, Y.F. Xia, Y. Fang, F.H. Meng*, J. Zhang, R. Cheng, C. Deng, and Z.Y. Zhong*, Selective Cell Penetrating Peptide-Functionalized Polymersomes Mediate Efficient and Targeted Delivery of Methotrexate Disodium to Human Lung Cancer In Vivo, Adv. Healthcare Mater.2018, 7, 1701135.

31.  X.X. Wang, R. Cheng*, L. Cheng, and Z.Y. Zhong*,Lipoyl ester terminated star PLGA as a simple and **art material for controlled drug delivery application, Biomacromolecules 2018, 19, 1368-1373.

32.  Y.Q. Zhu, Y. Jiang, F.H. Meng, C. Deng, R. Cheng, J. Zhang*, J. Feijen*, and Z.Y. Zhong*, Highly efficacious and specific anti-glioma chemotherapy by **art tandem nanomicelles co-functionalized with brain tumor-targeting and cell-penetrating peptides,J. Control. Release2018,278, 1-8.

33.  Y.Q. Zhu, J. Feijen*, and Z.Y. Zhong*, Dual-Targeted Nanomedicines for Enhanced Tumor Treatment,Nano Today2018, 18, 65-85.

34.  M. Qiu, H.L. Sun, F.H. Meng, R. Cheng, J. Zhang, C. Deng*, and Z.Y. Zhong*, Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo, J. Control. Release2018, 272, 107-113.

35.  W.J. Yang, Y.F. Xia, Y. Zou, F.H. Meng*, J. Zhang, and Z.Y. Zhong*, Bioresponsive chimaeric nano-polymersomes enable targeted and efficacious protein therapy for human lung cancers in vivo, Chem. Mater.2017, 29, 8757-8765.

36.  Y. Fang, W.J. Yang, L. Cheng*, F.H. Meng*, J. Zhang, and Z.Y. Zhong*, EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo, Acta Biomaterialia 2017, 64, 323-333.

37.  Y. Zou, M. Zheng, W.J. Yang, F.H. Meng*, K. Miyata, H.J. Kim, K. Kataoka*, and Z.Y. Zhong*, Virus-Mimicking Chimaeric Polymersome Boosts Targeted Cancer siRNA Therapy in Vivo, Adv. Mater.2017, 29, 1703285

38.  J.T. Wu, C. Deng*, F.H. Meng, J. Zhang, H.L. Sun, and Z.Y. Zhong*, Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer, J. Control. Release2017, 259, 76-82.

39.  Y. Zou, Y.H. Wei, G.L. Wang, F.H. Meng*, M.Y. Gao, G. Storm, and Z.Y. Zhong*, Nano-Polymersomes with an Ultrahigh Iodine Content for High-Performance X-Ray Computed Tomography Imaging In Vivo, Adv. Mater.2017, 29, 1603997.

40.  Y.Q. Zhu, X.X. Wang, J. Zhang, F.H. Meng, C. Deng, R. Cheng, J. Feijen*, and Z.Y. Zhong*, Exogenous vitamin C boosts the antitumor efficacy of paclitaxel containing reduction-sensitive shell-sheddable micelles in vivo, J. Control. Release2017, 250, 9-19.